c-myc

CMYC-Seminar: "The dual specificity MAP kinase phosphatase DUSP2 acts as distal regulatory node in T Cell signalling” by Professor Ole Morten Seternes
2025-10-22 14:00 - 15:00 (Europe/Oslo)
Welcome to the upcoming seminar holdt by Professor Ole Morten Seternes, Group Leader of the Cell Signalling and Targeted Therapy Research Group, Department of Pharmacy, UIT The Arctic University of Norway.
Tittle: The dual specificity MAP kinase phosphatase DUSP2 acts as distal regulatory node in T Cell signalling
Time: 22nd October 2025. 14:00 – 15:00
Place: Room B307, 3rd floor, Sentralblokken, Haukeland University Hospital
Abstract:
The dual-specificity MAP kinase phosphatases (MKPs) family plays a critical role in the dephosphorylation and inactivation of various MAP kinases in mammalian cells and tissues. MKPs not only provide a mechanism for spatiotemporal feedback control of these essential signalling pathways but also facilitate crosstalk between distinct MAP kinase pathways and other key signalling modules. The ten mammalian MKPs differ in their substrate specificity and subcellular localization. Several MKPs have been implicated in regulating MAPK signalling in T cells. However, studies utilizing genetic mouse models have yielded conflicting results regarding which MKP members contribute to this regulation. This prompted us to re-examine the role of MKPs in controlling MAPK signalling using a human T cell model. Our findings suggest that DUSP2 regulates early MAPK activation in these cells and may function as a part of a distal regulatory node in T cell signalling.

ESHAML2025
2025-10-16 08:00 - 2025-10-18 17:00
7th International Conference: Acute Myeloid Leukemia “Molecular and Translational”: Advances in Biology and Treatment
Estoril, Portugal

Presentations by CMYC participants at the conferences

ESHCML2025
2025-10-10 08:00 - 2025-10-12 17:00
ESH-iCMLf 27th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy

Estoril, Portugal – #ESHCML2025

Presentations by CMYC participants at the conferences

Nordic AML Group Meeting 2025
2025-09-10 - 2025-09-12 | Hotel Norge by Scandic, Nedre Ole Bullsplass 4, Bergen, Norway
We are delighted to invite you to Bergen, Norway, for the upcoming Nordic AML Meeting, taking place in September 10-12, 2025.
Set against the breathtaking backdrop of Bergen’s stunning fjords and vibrant cultural heritage, this event will bring together leading minds, practitioners, and innovators in the field of AML. It is an unparalleled opportunity to share knowledge, foster collaboration, and explore the latest advances in research and treatment strategies.
Save the dates and join us for an inspiring program filled with impactful discussions, cutting-edge insights, and the chance to connect with colleagues from across the Nordic region and beyond.
We look forward to welcoming you to Bergen for this exciting meeting!

Register here.
Registration deadline: 1st of August.
Read more at: https://www.namlg.org/namlg-bergen-2025/

c-myc Seminar
2025-08-21 13:00 - 14:00 | Birkhaugsalen (D303), 3rd floor, Central Block, Haukeland University Hospital
13:00 –Assoc. Prof. Morten Rye, Dept. of Clinical and Molecular Medicine, NTNU: Spatial Transcriptomics Analysis of Prostate Cancer
The cancerous prostate gland is a heterogenous mix of different cancer and normal cells and tissue types, which is a major source of confounding when large scale molecular – omics analysis is performed on the prostate gland. One way to delineate this heterogeneity is Spatial Transcriptomics, which can generate individual tissue specific gene expression profiles from thousands of spots placed on a grid across a prostate cancer tissue slice (see illustration). A major clinical challenge in prostate cancer is the ability to distinguish aggressive and non-aggressive prostate cancer in the cancer care pathway, and Spatial Transcriptomics could be a technology to do more precise molecular diagnostics of prostate cancer. With this in mind, our Prostomics research group generated spatial transcriptomics datasets (Visium 10x Genomics) on 32 tissue samples from 8 prostate cancer patients, 5 containing aggressive and 3 containing non- aggressive cancers. Samples were taken specifically from cancer, cancer-adjacent and distant normal tissue regions, and spots where classified according to their content of cancer, extracellular matrix/stroma and normal tissue, and further analysed by Gene Set Enrichment Analysis. Our analysis discovered that normal appearing tissue adjacent to aggressive cancer regions lose prostate specific functions and adapt properties resembling cell-types which are not expected to be present in a healthy prostate gland.

13:20 –Prof. Berit Johansen, Dept. of Biology, NTNU: Treating cancer and leukemia: A new way to trigger cell self-destruction
The polyunsaturated fatty acid arachidonic acid (AA) and its metabolites, eicosanoids, i.e. prostaglandins, thromboxanes, leukotrienes, etc., have attracted considerable interest in relation to inflammatory processes and diseases, including cancer (leukemia), cardiovascular and autoimmune diseases, and metabolic disorders. AA is generated by the action of phospholipase A2 (PLA2), which catalyzes its hydrolytic cleavage from membrane glycerophospholipids. PLA2 enzymes constitute a superfamily of enzymes, divided into many groups and subgroups. Among them, cytosolic Group IVA PLA2 (cPLA2α) plays a critical role in the release of AA and is the most well-studied PLA2 in inflammation. Targeting eicosanoid production by inhibiting cPLA2α offers a promising approach for inflammation or cancer therapy. Our findings imply cPLA2α may support cancer by mitigating oxidative stress and inhibiting tumor suppressor expression suggesting that the very specific and sensitive cPLA2α -inhibitors we have developed, has potential for treating acute leukemias and other cancers by introducing programmed cell death.

Master's Degree Examination for Stine Haugstvedt
2025-08-21 10:15 - 14:00 | Birkhaugsalen (D303), 3rd floor, Central Block, Haukeland University Hospital
Stine Haugstvedt will present and defend her Master’s thesis:
“Optimizing single-cell and immune profiling of asciminib-treated chronic myeloid leukemia patients using mass cytometry”

Date: Thursday, August 21
Time: 10:15 AM
Location: Birkhaugsalen, D305, 3rd floor, Central Block, Haukeland University Hospital

Supervisors:

Assoc. Prof. Morten Beck Rye (NTNU)
Prof. Bjørn Tore Gjertsen (UiB)
Dr. Stein-Erik Gullaksen (UiB)

Internal Examiner: Prof. Berit Johansen (NTNU)
External Examiner: Dr. David Micklem (BerGenBio)
Presentations Following the Master’s Examination

13:00 –Assoc. Prof. Morten Beck Rye, Dept. of Clinical and Molecular Medicine, NTNU
Spatial Transcriptomics Analysis of Prostate Cancer
13:20 –Prof. Berit Johansen, Dept. of Biology, NTNU
Treating cancer and leukemia: A new way to trigger cell self-destruction

Møte i Brukerutvalget
2025-05-21
Program/saksliste
1700-1730: «Generell informasjon om brukermedvirkning» med Merete Eide Hernes og Trude Hjortland Fra Seksjon for samhandling, Helse Bergen
1730-1745: «Dendrittcellevaksine ved KML» ved Morten Yong Isaksen
1745-1800: «The Hovon 135 study : a Single cell approach» ved Oriol Castell
1800-1810: Pause
1810-1830: Brukerutvalgets rolle og mandat i C-MYC ved Roger Strand
1830-1840: Status oppdatering fra C-MYC senteret ved Bjørn Tore Gjertsen

Innovasjonsseminar
2025-05-19 14:00 - 14:45
Er du nysgjerrig på gründerskap og innovasjon?
Vil du bli inspirert av en ekspert på fagfeltet?
Foredragsholder: Sjur Dagestad
Tid: 19. Mai 2025 kl 14.00-14.45
Sted: Birkhaugssalen, Sentralblokken, HUS
Sjur Dagestad vil ta oss med på en liten rundreise innen faget innovasjon. Sjur har jobbet med innovasjon siden 1988, både som gründer, leder og professor. Han var første vinner av Reodorprisen, har ledet Tomras satsning på radikal innovasjon og vært med på å starte flere selskaper. Han har skrevet åtte innovasjonsfaglige bøker og leder for tiden Norges største innovasjonsfaglige dypdykk, med 185 deltakere. Sjur vil komme inn på noen grunnleggende sider ved gründerskap, forskjellen på forskning og innovasjon og hvorfor det enkle ofte er det vanskeligste.

c-myc Single Cell Satellite Seminar 2025
2025-05-12 | Solstrand Hotel & Bad, Solstrandvegen 200, Os, 5200, Norway

CCBIO seminar – Stein-Erik Gullaksen
2025-04-24 14:30 - 15:30
Welcome to the CCBIO seminar series in the spring term of 2025. Open to all in auditorium 4, BBB. No registration necessary. Speaker is Stein-Erik Gullaksen from CCBIO/UiB, on the topic “Deep single cell immune and signaling profiling hours after starting treatment predict response to treatment in patients with Chronic myeloid leukemia.”
Read more on CCBIO’s website.

CCBIO Seminar – Göran Karlsson
2025-03-27 14:30 - 15:30
Welcome to the CCBIO seminar series in the spring term of 2025. Open to all in auditorium 4, BBB. No registration necessary. Speaker is Göran Karlsson from Lund University, Sweden, on the topic “Exposing the stem cells of CML using single-cell genomics”.
Read more at CCBIO’s website.
